← All trials
NCT05740280
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2023
- Primary completion
- Aug 17, 2023
- Completion date
- Aug 17, 2023
- First posted
- Feb 23, 2023
- Last posted
- May 26, 2023
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cellivery Therapeutics, Inc.Lead sponsor
- LabCorpCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.